YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
The EMBO Journal · 15.02.2023 · 42 (4)
DOI: 10.15252/embj.2022112184 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Journal, online erschienen am 02.01.2023. Verfasst von Xu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Transcription Factors, Prostatic Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDCR NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Hippo signaling restricts tumor growth by inhibiting the oncogenic potential of YAP/TAZ-TEAD transcriptional complex. Here, we uncover a context-dependent tumor suppressor function of YAP in androgen receptor (AR) positive prostate cancer (PCa) and show that YAP impedes AR+ PCa growth by antagonizing TEAD-mediated AR signaling. TEAD forms a complex with AR to enhance its promoter/enhancer occupancy and transcriptional activity. YAP and AR compete for TEAD binding and consequently, elevated YAP in the nucleus disrupts AR-TEAD interaction and prevents TEAD from promoting AR signaling. Pharmacological inhibition of MST1/2 or LATS1/2, or transgenic activation of YAP suppressed the growth of PCa expressing therapy resistant AR splicing variants. Our study uncovers an unanticipated crosstalk between Hippo and AR signaling pathways, reveals an antagonistic relationship between YAP and TEAD in AR+ PCa, and suggests that targeting the Hippo signaling pathway may provide a therapeutical opportunity to treat PCa driven by therapy resistant AR variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Center for Cancer Targeted Therapies, Signet Therapeutics Inc., Research Institute of Tsinghua University in Shenzhen, Shenzhen, China.
- Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.
- Harvard Stem Cell Institute, Boston, MA, USA.
- Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
- Department of General Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Förderung
- NIGMS NIH HHS
- NIDCR NIH HHS
- NCI NIH HHS
- HHS ¦ NIH ¦ National Cancer Institute
- HHS ¦ NIH ¦ National Institute of General Medical Sciences
- Welch Foundation
Zitieren
APA
Li, X., Zhuo, S., Cho, Y. S., Liu, Y., Yang, Y., Zhu, J., & Jiang, J. (2023). YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth. The EMBO Journal, 42(4). https://doi.org/10.15252/embj.2022112184
Vancouver
Li X, Zhuo S, Cho YS, Liu Y, Yang Y, Zhu J, et al. YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth. The EMBO Journal. 2023;42(4). doi:10.15252/embj.2022112184
BibTeX
@article{Li2023,
author = {Li, Xu and Zhuo, Shu and Cho, Yong Suk and Liu, Yuchen and Yang, Yingzi and Zhu, Jian and Jiang, Jin},
title = {YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth},
journal = {The EMBO Journal},
year = {2023},
volume = {42},
number = {4},
doi = {10.15252/embj.2022112184}
}
EUVIMED